Can DRL’s New Product Launches Offset the Slowdown in Revlimid Sales?
Dr. Reddy's Laboratories (DRL), a prominent player in the pharmaceutical industry, has been witnessing a notable slowdown in sales of its generic version of Revlimid (lenalidomide), a popular cancer drug, especially in the highly competitive US market. [...]
